Patients who received MRI-guided focused ultrasound during standard-of-care chemotherapy had an almost 40% increase in overall survival, according to a study published Nov. 24 in the Lancet Oncology.
Led by a team from Baltimore-based University of Maryland School of Medicine, researchers used the technique to open the blood-brain barrier while chemotherapy was delivered to a brain tumor site after surgery.
Thirty-four patients participated in the trial. Their results were matched to a control group of 185 glioblastoma patients with similar characteristics who received a standard dose of chemotherapy without receiving focused ultrasound, according to a Nov. 25 news release from the university.
“Trial participants had nearly 14 months of median progression-free survival, compared to eight months in the control group” and “lived for more than 30 months compared to 19 months in the control group,” the release said.
Read the full study here.
Leave a Reply